Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.

Autor: Shea LK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Honjo K; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Redden DT; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA., Tabengwa E; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Li R; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Li FJ; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Shakhmatov M; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Chiorazzi N; Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA., Davis RS; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. rsdavis@uab.edu.; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. rsdavis@uab.edu.; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA. rsdavis@uab.edu.; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. rsdavis@uab.edu.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2019 May 15; Vol. 9 (6), pp. 47. Date of Electronic Publication: 2019 May 15.
DOI: 10.1038/s41408-019-0207-7
Databáze: MEDLINE